MRF-Logo2019-Horizontal-RGB
New Reseaech
REGISTER
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Content within the patient forum is user-generated and has not been reviewed by medical professionals. Other sections of the Melanoma Research Foundation website include information that has been reviewed by medical professionals as appropriate. All medical decisions should be made in consultation with your doctor or other qualified medical professional.

New Reseaech

› Forums › General Melanoma Community › New Reseaech

  • Post
Viewing 1 reply thread
  • Replies
      • June 21, 2011 at 8:48 pm
      lhaley
      Participant

        What was the result of the DTIC vs Tem.  ?  I can't remember by password so I can't get in.

        Thanx

          • June 21, 2011 at 8:52 pm
          MichaelFL
          Participant

            Here it is from Pub Med, may be easier to access.

            http://www.ncbi.nlm.nih.gov/pubmed/21600759

            RESULTS:

            Median OS was 9.1months in the temozolomide arm and 9.4months in the dacarbazine arm, with a hazard ratio (HR) of 1.00 (95%confidence interval [CI]: 0.86, 1.17; P=0.99). Median progression-free survival (PFS) was 2.3months in the temozolomide arm and 2.2months in the dacarbazine arm, with a HR of 0.92 (95%CI: 0.80, 1.06; P=0.27). In patients with measurable disease, overall response rate was higher in the temozolomide arm than in the dacarbazine arm (14.5% versus 9.8%, respectively), but the median duration of response was longer for dacarbazine. The extended schedule, escalated dose temozolomide arm showed more toxicity than the standard dose, single agent dacarbazine arm. The most common non-haematological treatment emergent adverse events reported in both treatment arms were nausea, fatigue and vomiting and constipation.

            • June 21, 2011 at 8:52 pm
            MichaelFL
            Participant

              Here it is from Pub Med, may be easier to access.

              http://www.ncbi.nlm.nih.gov/pubmed/21600759

              RESULTS:

              Median OS was 9.1months in the temozolomide arm and 9.4months in the dacarbazine arm, with a hazard ratio (HR) of 1.00 (95%confidence interval [CI]: 0.86, 1.17; P=0.99). Median progression-free survival (PFS) was 2.3months in the temozolomide arm and 2.2months in the dacarbazine arm, with a HR of 0.92 (95%CI: 0.80, 1.06; P=0.27). In patients with measurable disease, overall response rate was higher in the temozolomide arm than in the dacarbazine arm (14.5% versus 9.8%, respectively), but the median duration of response was longer for dacarbazine. The extended schedule, escalated dose temozolomide arm showed more toxicity than the standard dose, single agent dacarbazine arm. The most common non-haematological treatment emergent adverse events reported in both treatment arms were nausea, fatigue and vomiting and constipation.

            • June 21, 2011 at 8:48 pm
            lhaley
            Participant

              What was the result of the DTIC vs Tem.  ?  I can't remember by password so I can't get in.

              Thanx

          Viewing 1 reply thread
          • You must be logged in to reply to this topic.
          About the MRF Patient Forum

          The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

          The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.

          Popular Topics